EKF Diagnostics Holdings plc appointment of CEO

EKF Diagnostics Holdings plc, the AIM-listed global diagnostics business, announces the appointment of Gavin Jones as Chief Executive Officer and to the EKF Board, with immediate effect. Gavin previously served as Chief Product Officer at EKF and has extensive industry experience in Analytical Chemistry and Diagnostics. Julian Baines will remain as Executive Chair for the foreseeable future.

In his role as Chief Product Officer, Gavin led the Product Management, R&D, Marketing, and Regulatory departments, bringing new and updated products to market and delivering enhanced connectivity solutions and user-friendly design to meet evolving customer needs. Before joining EKF in 2013, Gavin held a Product Management role at Biotage AB and analyst positions at PCI (then trading as Penn Pharma) and the Forensic Science Service, initially starting in the laboratory but quickly transitioning to product strategy and innovation. His expertise spans commercial strategy, business development, and product lifecycle management, contributing to significant growth in global healthcare markets.

Gavin holds a BSc (Hons) Forensic and Biomolecular Science degree from Liverpool John Moores University and has a track record of driving product innovation and operational excellence. Gavin is committed to expanding EKF’s Point-of-Care solutions and strengthening its market presence in Life Sciences. 

Julian Baines, Executive Chair of EKF, commented: “I’m delighted that Gavin Jones is taking on the role of Chief Executive Officer and joining the Board. Gavin has over twenty years of experience in Point-of-Care and Life Sciences and has been instrumental in driving the commercial success of many of our products. Many shareholders have met Gavin over the last year or so as he’s become more and more involved in the senior leadership team. Gavin has ambitious plans for delivering sustainable growth and unlocking the unrealized potential that our core products and services hold. We have an exciting opportunity to increase our commercial investment to drive organic growth, and I’m delighted that Gavin will lead that process.”